Antifungal drug tested as potential brain tumor treatment
NCT ID NCT04825275
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This early-phase study tested whether the antifungal drug posaconazole can enter brain tumors in high enough amounts to stop cancer cells from dividing. Seven adults with glioblastoma took the drug before surgery so researchers could measure drug levels in their spinal fluid and tumor tissue. The study was terminated early, but the results help decide if further research is worthwhile.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.